6-甲基-2-(吡咯烷-2-基)-1H-1,3-苯并二唑 | 885278-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 6-甲基-2-(吡咯烷-2-基)-1H-1,3-苯并二唑
• 中文别名: 5-甲基-2-吡咯烷-2-基-1H-苯并咪唑二盐酸盐
• 英文名称: 6-Methyl-2-pyrrolidin-2-YL-1H-benzoimidazole
• 英文别名: 6-methyl-2-pyrrolidin-2-yl-1H-benzimidazole
• CAS: 885278-00-2
• 化学式: C₁₂H₁₅N₃
• mdl: MFCD06738999
• 分子量: 201.27
• InChiKey: GHTGLFGDGAUKFP-UHFFFAOYSA-N

物化性质

• 沸点：
  443.9±38.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

文献信息

• Benzimidazole-imidazole Derivatives
  申请人：Vandyck Koen

  公开号：US20120219594A1

  公开（公告）日：2012-08-30

  Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR 1 R 2 R 3 , aryl, heteroaryl or heteroC 4-6 cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  公式I的HCV复制抑制剂包括立体化学异构形式以及其盐、溶剂合物，其中R和R′分别独立地是—CR1R2R3、芳基、杂芳基或杂C4-6环烷基，其中芳基和杂芳基可以选择性地被卤素和甲基中的1或2个取代基取代。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HCV治疗中的应用。
• [EN] ANTI-VIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ABBVIE INC

  公开号：WO2012116257A1

  公开（公告）日：2012-08-30

  Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  本发明描述了抑制丙型肝炎病毒（“HCV”）复制的有效化合物。本发明还涉及制备这种化合物的过程，包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• Benzimidazole-imidazole derivatives
  申请人：JANSSEN R&D IRELAND

  公开号：US20140107172A1

  公开（公告）日：2014-04-17

  Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR 1 R 2 R 3 , aryl, heteroaryl or heteroC 4-6 cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  公式I包括立体化学异构体形式及其盐、溶剂化物，用于抑制丙型肝炎病毒复制的抑制剂，其中R和R'各自独立地为—CR1R2R3、芳基、杂芳基或杂C4-6环烷基，其中芳基和杂芳基可以选择性地被1或2个卤素和甲基取代。本发明还涉及制备所述化合物的工艺、含有它们的制药组合物以及它们在丙型肝炎病毒治疗中的应用。
• ANTI-VIRAL COMPOUNDS
  申请人：AbbVie Bahamas Ltd.

  公开号：EP2678334B1

  公开（公告）日：2017-03-22
• SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Zhang Jiancun

  公开号：US20140147412A1

  公开（公告）日：2014-05-29

  Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.